CLO26-101: Comparison of Clinical and Pathological Tumour Staging Following CDK4/6 Inhibitor-Based Neoadjuvant Therapy in HR+/HER2− Breast Cancer
20260 citationsJournal Article
Field-Weighted Citation Impact: 0.00
CLO26-101: Comparison of Clinical and Pathological Tumour Staging Following CDK4/6 Inhibitor-Based Neoadjuvant Therapy in HR+/HER2− Breast Cancer | Researchclopedia